The Power of Nuclear Medicine

For 20 years, Karin Stephenson studied medical isotopes. Then she saw their impact when they helped save her mother’s life.

With more than twenty years of experience in the field of radiopharmaceuticals, Karin Stephenson, Director of Nuclear Research and Education Support at McMaster University, knows everything there is to know about medical isotopes – how they work, how they are produced, how they can be used to diagnose and treat cancer, and how to make them better.

And ten years ago, she saw the impact they can have when they helped save her mother’s life.

Want to learn more?

Sign up to receive future communications from McMaster University

Meet John Valliant, the scientist-entrepreneur behind one of the largest acquisitions in Canadian university history

Fusion Pharmaceuticals, a radiopharmaceutical company founded by McMaster researcher John Valliant, uses nuclear medicine to develop next-generation cancer therapies that target cancer cells directly, providing patients with more effective and precise treatments with reduced side effects.

And it was recently acquired by AstraZeneca for $2 billion.

An idea scribbled on a napkin grew into a company that not only provides better treatments for cancer patients; it also strengthens local and national economics and trains the next generation of scientists.

Learn more about Fusion Pharmaceuticals.

Want to learn more?

Sign up to receive future communications from McMaster University